Drugs / Resatorvid
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07092215 | Jun → Jul 2025 | — | Stefan Heber | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04620148 | Dec 2021 → Dec 2022 | liver disorder | Akaza Bioscience Ltd | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00633477 | Feb 2008 → Feb 2009 | infectious disease with sepsis | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00143611 | Sep 2005 → Feb 2007 | infectious disease with sepsis | Takeda | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06890039 Comparator | Sep 2025 → Feb 2026 overdue | alcoholic hepatitis, alcoholic liver cirrhosis | Yaqrit Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Resatorvid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00633477 ↗ |
| Known as | Cli-095 | ChEMBL registry synonym — accepted as the source's own label CHEMBL225157 ↗ |
| Known as | TAK-242 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04620148 ↗ |
| Action | Inhibit | “acts by inhibiting TLR-4 mediated signaling” NCT00143611 ↗ |
| Modality | Small molecule | “TAK-242 (resatorvid) is a small molecule suppressor of pathogen-induced release of inflammatory cytokines” NCT00143611 ↗ |
| Route | Subcutaneous | “injection, subcutaneously for thirty minutes” NCT00143611 ↗ |
| Target | TLR4 | “Resatorvid This TLR4 antagonist” NCT07092215 ↗ |